Join host, Carmel Fisher for an exclusive conversation with Christopher Schaber, CEO of Soligenix Inc. (NASDAQ: SNGX), as we explore the company's exciting clinical developments in rare disease therapeutics.

With positive interim results from their extended HyBryte™ treatment study and enrollment now open for both their confirmatory Phase 3 CTCL trial and Phase 2 Behçet's Disease study, Soligenix is advancing multiple promising programs simultaneously.

Schaber discusses the clinical differentiation of HyBryte™, which continues showing improvement even after treatment stops, the company's international expansion strategy through their new  ...